Johnson & Johnson (JNJ) Stock Price & Analysis
Johnson & Johnson (JNJ) — MoonshotScore 84/100 (Exceptional band), calculated Nov 22, 2026. Price $270.47 (+1.25%), as of the Nov 20, 2026 trading session; market cap $651B. Expected results Jan 20, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 37.79× (market value Nov 20, 2026; cash Sep 27, 2026) · expected results Jan 20, 2027
Johnson & Johnson · JNJ · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-13: Johnson & Johnson combines prescription medicines with devices used in surgery, orthopaedics, vision care and interventional treatment. Its scale matters less than whether rising sales can keep translating into durable operating profit and cash generation across Innovative Medicine and MedTech.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Johnson & Johnson (JNJ)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Jan 20, 2027
- Altman Z 5.39 · Piotroski F 6
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 87 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional |
The score moved from 83 in the stored Nov 21, 2026 snapshot to 84 in the current publication computed Nov 22, 2026 (+1); the largest pillar moves were Business Quality +1 and Valuation -1. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $270.476.8% below its 5-year high of $290.25 () | |
| Change on the day | +1.25% | |
| 52-week range | $199.91–$290.25 | |
| Market capitalisation | $651B | |
| Price / earnings (trailing) | 41.01 | |
| Shares traded on the day | 11.92M | |
| Beta (volatility vs the S&P 500) | 0.24 | |
| Dividends per share (last 12 months) | $5.28 | |
| Dividend yield (last 12 months) | 1.95% |
Why Johnson & Johnson scores 84

Drugs and medical devices together give this healthcare giant a high quality reading. Litigation and a full price keep the valuation pillar middling.
Share price, last 12 months +31.0%
$193.72 $253.79
What the price assumes
14.6% a year of free-cash-flow growth for ten years is what a $651.00B market value () asks for.
The price asks for faster cash-flow growth than recent years. That depends on the drug pipeline and the medtech business.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $18.71B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 9 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 1.7% either way.
- -2.2%Jan ’24
- -1.9%Apr ’24
- +2.9%Jul ’24
- +1.7%Oct ’24
- -1.0%Jan ’25
- -0.3%Apr ’25
- +5.0%Jul ’25
- +0.1%Oct ’25
- +0.1%Jan ’26
- +0.3%Apr ’26
- -1.5%Jul ’26
- -3.7%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | In line | -3.7% | — | |
| Beat | In line | -1.5% | +0.7% | |
| In line | Beat | +0.3% | -5.0% | |
| In line | Beat | +0.1% | +4.4% | |
| Beat | Beat | +0.1% | +0.5% | |
| Beat | Beat | +5.0% | +9.0% | |
| Beat | Beat | -0.3% | +0.6% | |
| Beat | In line | -1.0% | +2.0% | |
| Beat | Beat | +1.7% | +1.1% | |
| Beat | In line | +2.9% | +3.5% | |
| Beat | In line | -1.9% | +1.3% | |
| In line | Beat | -2.2% | -2.3% |
Results beat routinely, and the shares barely react. Litigation and pipeline news move the stock more.
Our track record on this stock
Since the score went from 89 to 83 while the share price moved -0.9% through .
The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 53% of 40 rate it a buy; the average target ($285.31, captured ) sits +5.5% from the price of $270.47.
- Last 90 days: 13 rating actions, every one a reaffirmation.
- Our signals: Exceptional band; strongest pillar Business Quality (90), weakest Valuation (41).
Analysts are split on the healthcare giant, mostly over litigation. Our model scores the cash generation, which has stayed steady.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · in line with the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
As a result, we are raising our guidance for 2026 versus our most recent update in July.
Joseph J. Wolk · Statement from
We are also tightening the range of our effective tax rate guidance Based on our year to date results, we now expect a full year effective tax rate of 17.0% to 17.5%. Given those updates, we now expect adjusted operational earnings per share in the range of $10.95 to $11.05, or 2% at the midpoint.
Joseph J. Wolk · Statement from
How to read these dates
Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Johnson & Johnson (JNJ): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 22, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Johnson & Johnson (JNJ), and what does it report?
Short answer · as of
Johnson & Johnson is a healthcare holding company, not merely a diversified drugmaker. Innovative Medicine sells therapies spanning oncology, immunology, neuroscience and other disease areas, while MedTech supplies products tied to procedures and clinical care.
Research dated 2026-09-13.
Innovative Medicine contributes more revenue, but consolidated sales and profit blend pharmaceutical demand with activity in surgery, orthopaedics, vision and interventional treatment. That reporting shape means a movement in the company total may originate from very different product and customer dynamics.
What do the latest results show for Johnson & Johnson (JNJ)?
Research dated 2026-09-13.
The latest quarter showed sequential gains in revenue, gross profit, operating profit, net income and diluted earnings. Revenue and the earnings measure compared with consensus also exceeded expectations, extending a record of meeting or surpassing the displayed estimates.
Cash generation improved from the preceding quarter, although it remained below stronger periods in the recent series. Separately, management said the planned Firefly Bio acquisition would add an antibody platform and reinforce the oncology portfolio; that is a strategic claim, not an explanation for the reported improvement.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $25.40B Sep 27, 2026
- Latest quarter · R&D
- $4.65B Sep 27, 2026
- Latest quarter · SG&A
- $6.29B Sep 27, 2026
- Latest quarter · FMP standardized operating result
- $5.84B Sep 27, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 27, 2026 | $25.40B | $4.65B | $6.29B | $5.84B |
| Jun 28, 2026 | $25.31B | $3.65B | $6.43B | $7.17B |
| Mar 29, 2026 | $24.06B | $3.53B | $6.03B | $6.39B |
| Dec 28, 2025 | $24.56B | $4.25B | $6.75B | $5.59B |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $25.40B Oct 13, 2026
- Latest report · revenue estimate
- $25.38B Oct 13, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 13, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 13, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 13, 2026 | $25.40B | $25.38B | $2.5900 | $2.5200 |
| Jul 15, 2026 | $25.31B | $25.06B | $2.9000 | $2.8500 |
| Apr 14, 2026 | $24.06B | $23.61B | $2.7000 | $2.6800 |
| Jan 21, 2026 | $24.56B | $24.15B | $2.4600 | $2.4600 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $23.99B | $5.15B | $2.12 (diluted) |
| Q4 FY2025 | $24.56B | $5.12B | $2.10 (diluted) |
| Q1 FY2026 | $24.06B | $5.24B | $2.14 (diluted) |
| Q2 FY2026 | $25.31B | $5.53B | $2.27 (diluted) |
What are the financial strengths and risks for Johnson & Johnson (JNJ)?
Short answer · as of
Cash and short-term investments were $17.23B at the Sep 27, 2026 balance-sheet date. Operating cash flow was $7.72B for the quarter ended Sep 27, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Johnson & Johnson remains profitable at substantial gross and operating margins, and every displayed quarter generated positive operating cash flow after funding ongoing research activity. Recent cash generation also exceeded capital spending, while the financial quality and distress screens remain favorable.
Liquidity deserves a more qualified reading. Cash and short-term investments sit below total debt, quick assets do not cover current obligations, and the cash balance has retreated from its recent peak. Dividend payments continued at a higher per-share rate than earlier listed payments, leaving cash conversion, leverage and distributions linked through capital allocation.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 41.01 runs well above the Healthcare sector’s ~20.60x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $7.72B Sep 27, 2026
- Previous quarter · operating cash flow
- $8.62B Jun 28, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 27, 2026 | $7.72B | −$1.36B |
| Jun 28, 2026 | $8.62B | −$1.32B |
| Mar 29, 2026 | $2.51B | −$1.05B |
| Dec 28, 2025 | $7.31B | −$1.84B |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Johnson & Johnson (JNJ)?
Short answer · as of
The next earnings report is expected on Jan 20, 2027.
Research dated 2026-09-13.
The next earnings release should be read against the latest high revenue base and the established pattern of consensus outperformance. The useful checks are whether operating profit advances with sales, whether operating cash flow continues recovering, and whether cash stabilizes relative to debt.
Firefly Bio adds another checkpoint: completion would move the antibody platform from announced intent into the portfolio. Longer-range forecasts anticipate continuing revenue and earnings expansion, but analyst participation becomes progressively thinner, so execution across the operating segments matters more than the distant consensus path.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
As a reminder for your 2027 modeling, we expect Firefly Bio and Cell BioMedicines to have a combined dilutive impact of $1.36 per share on a full year adjusted earnings per share next year.
Joseph J. Wolk ·
How does Johnson & Johnson compare with its peers?
Short answer
Johnson & Johnson's score ranks tied for 6th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with a pure pharmaceutical company, Johnson & Johnson carries direct exposure to procedure volumes through surgery, orthopaedics, vision and interventional products. Compared with a pure medical-device company, its larger revenue engine is Innovative Medicine. Consolidated results therefore combine therapeutic product cycles with procedure-linked demand, and weakness in one business need not describe the other.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1347.11 Nov 20, 2026 | $1.27T | 98 5-pillar Nov 22, 2026 | |
| $37.82 Nov 20, 2026 | $167B | 87 5-pillar Nov 22, 2026 | |
| $46.52 Nov 20, 2026 | $112B | 87 5-pillar Nov 22, 2026 | |
| $174.35 Nov 20, 2026 | $270B | 85 5-pillar Nov 22, 2026 | |
| $58.80 Nov 20, 2026 | $120B | 85 5-pillar Nov 22, 2026 | |
| Johnson & Johnson (JNJ) — this page | $270.47 | $651B | 84 |
| $286.20 Nov 20, 2026 | $506B | 84 5-pillar Nov 22, 2026 | |
| $435.64 Nov 20, 2026 | $236B | 84 5-pillar Nov 22, 2026 | |
| $150.47 Nov 20, 2026 | $284B | 83 5-pillar Nov 22, 2026 | |
| $47.76 Nov 20, 2026 | $95.7B | 77 5-pillar Nov 22, 2026 | |
| $339.85 Nov 20, 2026 | $305B | 76 5-pillar Nov 22, 2026 | |
| $166.43 Nov 20, 2026 | $206B | 73 5-pillar Nov 22, 2026 | |
| $133.72 Nov 20, 2026 | $330B | 68 5-pillar Nov 22, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $260.00 – $320.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $285.31
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $281.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 35
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 11
- Other transactions
- 24
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 73.1% Period end Sep 30, 2026
- Previous quarter · ownership
- 74.5% Prior to period end Sep 30, 2026
- Reporting holders
- 4,863 Period end Sep 30, 2026
- Previous quarter · holders
- 4,831 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 209,718,001 |
| Vanguard Capital Management LLC | 157,757,243 |
| State Street Corp | 133,971,339 |
| Vanguard Portfolio Management LLC | 65,651,392 |
| Geode Capital Management, LLC | 65,497,363 |
Tracked investors
Which of the 16 named investors we follow held JNJ in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.63% | $144.95M | Trimmed −18.2% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
JNJ Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is Johnson & Johnson more than a drugmaker?
Innovative Medicine is the larger segment, but MedTech also sells products used in surgery, orthopaedics, vision care and interventional treatment. The company therefore participates in medicine demand and procedure-linked healthcare spending.
Which Johnson & Johnson business contributes more revenue?
Innovative Medicine contributes more revenue than MedTech. Its portfolio spans oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolic care, and pulmonary hypertension.
How does MedTech change Johnson & Johnson’s business mix?
MedTech adds products whose use is tied to clinical procedures and surgical activity, creating demand drivers distinct from prescription medicines. That makes the consolidated revenue line a blend of therapy uptake and healthcare procedure activity.
What would Firefly Bio add to Johnson & Johnson?
Management says the planned acquisition would add another antibody platform and strengthen next-generation oncology work. The immediate point to watch is whether the transaction closes and moves from planned expansion into the operating portfolio.
What is the JNJ stock price today?
The last price recorded for Johnson & Johnson (JNJ), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the JNJ price target?
The last analyst consensus price target we captured for Johnson & Johnson (JNJ), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 82 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 2 with no recorded source, 5 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold JNJ
Funds in our ETF coverage that list JNJ among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Evolved U.S. Innovative Healthcare ETF (IEIH) | 10.24% | |
| PBPH ETF | 9.35% | |
| VHT ETF | 8.22% | |
| ProShares - Ultra Health Care (RXL) | 7.33% | |
| IXJ ETF | 7.22% | |
| Brookstone Value Stock ETF (BAMV) | 4.64% | |
| iShares MSCI USA Momentum Factor ETF (MTUM) | 4.53% | |
| Simplify Health Care ETF (PINK) | 4.48% | |
| GVLE ETF | 3.67% | |
| Nuveen Sustainable Core (NSCR) | 3.63% |